(12) International Application Status Report

Received at International Bureau: 12 December 2019 (12.12.2019)

Information valid as of: 17 September 2020 (17.09.2020)

Report generated on: 25 September 2020 (25.09.2020)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2020/10942804 June 2020 (04.06.2020) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/EP2019/08281027 November 2019 (27.11.2019) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
1819430.8 (GB)29 November 2018 (29.11.2018) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 47/69 (2017.01); A61P 35/00 (2006.01)

(71) Applicant(s):
MIDATECH LTD [GB/GB]; Oddfellows House 19 Newport Road Cardiff South Glamorgan CF24 0AA (GB) (for all designated states)

(72) Inventor(s):
PORTER, John; c/o Midatech Ltd Oddfellows House 19 Newport Road Cardiff South Glamorgan CF24 0AA (GB)
DING, Yao; c/o Midatech Ltd Oddfellows House 19 Newport Road Cardiff South Glamorgan CF24 0AA (GB)

(74) Agent(s):
MEWBURN ELLIS LLP; City Tower 40 Basinghall Street London Greater London EC2V 5DE (GB)

(54) Title (EN): THERAPEUTIC COMPOUNDS, NANOPARTICLES AND USES THEREOF
(54) Title (FR): COMPOSÉS THÉRAPEUTIQUES, NANOPARTICULES ET LEURS UTILISATIONS

(57) Abstract:
(EN): The present invention comprising a maytansinoid covalently bonded to a linker group, wherein the linker group is covalently bonded to a ligand group having a cyclic polythiol moiety. Also provided are nanoparticles and conjugates, including antibody-drug conjugates, comprising the compound. Furthermore, pharmaceutical compositions comprising the compounds, nanoparticles, and conjugates are provided. Also disclosed are uses of the compounds, nanoparticles, conjugates and pharmaceutical compositions in methods of treatment of proliferative disorders, including cancer.
(FR): La présente invention comprend un maytansinoïdes lié de manière covalente à un groupe lieur, le groupe lieur étant lié de manière covalente à un groupe ligand ayant une fraction polythiol cyclique. L'invention concerne également des nanoparticules et des conjugués, y compris des conjugués anticorps-médicament, comprenant le composé. L'invention concerne en outre des compositions pharmaceutiques comprenant les composés, les nanoparticules et les conjugués. L'invention concerne également des utilisations des composés, des nanoparticules, des conjugués et des compositions pharmaceutiques dans des procédés de traitement de troubles prolifératifs, y compris le cancer.

International search report:
Received at International Bureau: 25 February 2020 (25.02.2020) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Chapter II demand received: 07 September 2020 (07.09.2020)

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America